Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Renzhi Wang¹, Cuiqi Zhou², Ann I McCormack³, Adam N Mamelak⁴

Affiliations

¹ Department of Neurosurgery, Peking Union Medical College Hospital (CAMS), Beijing, China.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
³ Department of Endocrinology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
⁴ Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

PMID: 35355554
PMCID: PMC8959341
DOI: 10.3389/fendo.2022.868174

Editorial

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Renzhi Wang et al. Front Endocrinol (Lausanne). 2022.

. 2022 Mar 9:13:868174.

doi: 10.3389/fendo.2022.868174. eCollection 2022.

Authors

Renzhi Wang¹, Cuiqi Zhou², Ann I McCormack³, Adam N Mamelak⁴

Affiliations

¹ Department of Neurosurgery, Peking Union Medical College Hospital (CAMS), Beijing, China.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
³ Department of Endocrinology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
⁴ Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

PMID: 35355554
PMCID: PMC8959341
DOI: 10.3389/fendo.2022.868174

No abstract available

Keywords: diagnosis; drug resistance; medical therapy; pathogenesis; refractory pituitary adenomas; surgical treatment; temozolomide, targeted and immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with several of the authors (AIM, ANM).

Comment on

Editorial on the Research Topic Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments

Cited by

Everolimus in pituitary tumor: a review of preclinical and clinical evidence.
Yao Z, Chen H. Yao Z, et al. Front Endocrinol (Lausanne). 2024 Dec 16;15:1456922. doi: 10.3389/fendo.2024.1456922. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39736867 Free PMC article. Review.
Effects of Staged Nursing Care on Neuroendoscopic Transsphenoidal Pituitary Adenoma Resection and Postoperative Complications.
Fei Y, Zhang J, Gu Y. Fei Y, et al. Evid Based Complement Alternat Med. 2022 Aug 5;2022:2171529. doi: 10.1155/2022/2171529. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 6;2023:9758185. doi: 10.1155/2023/9758185. PMID: 35966740 Free PMC article. Retracted.
Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF, Ghorbani M, Panahi M, Nazem S, Karimi M, Salimi V, Tavakoli-Yaraki M. Taghavi SF, et al. Mol Biol Rep. 2023 Aug;50(8):6425-6434. doi: 10.1007/s11033-023-08523-0. Epub 2023 Jun 16. Mol Biol Rep. 2023. PMID: 37326745
The reporting quality of randomized controlled trials in pharmacotherapy for pituitary adenomas.
Yan H, Wang D, Zhao Y, Miao J, Wang Z. Yan H, et al. Medicine (Baltimore). 2024 Mar 15;103(11):e37518. doi: 10.1097/MD.0000000000037518. Medicine (Baltimore). 2024. PMID: 38489678 Free PMC article.

References

1. Dai C, Feng M, Liu X, Ma S, Sun B, Bao X, et al. . Refractory Pituitary Adenoma: A Novel Classification for Pituitary Tumors. Oncotarget (2016) 7(50):83657–68. doi: 10.18632/oncotarget.13274 - DOI - PMC - PubMed
1. Liu X, Dai C, Feng M, Li M, Chen G, Wang R. Diagnosis and Treatment of Refractory Pituitary Adenomas: A Narrative Review. Gland Surg (2021) 10(4):1499–507. doi: 10.21037/gs-20-873 - DOI - PMC - PubMed
1. Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, et al. . Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. J Clin Endocrinol Metab (2020) 105(3):e660–e675. doi: 10.1210/clinem/dgz211 - DOI - PubMed
1. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. . European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas. Eur J Endocrinol (2018) 178(1):G1–G24. doi: 10.1530/EJE-17-0796 - DOI - PubMed
1. Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD, et al. . Treatment and Long-Term Outcomes in Pituitary Carcinoma: A Cohort Study. Eur J Endocrinol (2019) 181(4):397–407. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Affiliations

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources